RBQM's $13.8M value driven 84% by Phase III timeline gains, with clinical phase durations shrinking up to 19% in oncology ...
CluePoints earns third Scrip Awards shortlisting in eight years for its risk-based quality management software serving ...
RBQM's full value exceeds current financial models, with omitted factors like rework reduction and inspection readiness ...
Vanda Pharmaceuticals' VQW-765 fails primary endpoint in Phase III social anxiety trial, showing no statistically significant ...
Entrada Therapeutics reports Phase 1/2 data for ENTR-601-45 in exon 45 skipping, the most common single-exon target affecting ...
When Boehringer Ingelheim went live with multiple Veeva Vaults simultaneously in 2025, the pharma world took notice. The "big bang" consolidation became one of the defining reference stories of that ...
“Study builds [in TrialKit] went from anywhere from two to six weeks to one to three to four days. The work Floyd is doing on ...
WCG's Activation Intelligence saves 20+ hours per study activation. Here's what that number means for site startup budgets ...
Proteomic aging clocks are moving into clinical trials, but FDA surrogate endpoint standards and assay reproducibility gaps ...
Heart failure Phase IV studies use digital tools and remote monitoring to reduce patient dropout when perceived personal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results